stomach ache on glp 1 Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus GLP-1 and Gut Health: Addressing

M.GathercoleL

Personalization extends to formulation choice as well

A 2025 systematic review and meta-analysis in eClinicalMedicine pooled data from 14 studies, including over 5.2 million patients, and found GLP-1 receptor agonists were associated with reduced alcohol intake, lower relapse rates, and fewer alcohol-related diagnoses

In addition, semaglutide, Liraglutide, and dulaglutide have indications for reducing cardiovascular risk in patients with T2DM and established atherosclerotic cardiovascular disease [113,114,115,116,117,118]

The net result is a measurable shift in appetites and diet patterns resulting in less processed food, and greater consumption of nutritionally dense, unprocessed items (Dilley et al., 2025)

Computational analysis of gynura bicolor bioactive compounds as dipeptidyl peptidase-IV inhibitor